Skip to main content

ORBIMED ADVISORS LLC

Position in LLY — ELI LILLY & Co

CIK 1055951 New York, NY

Position in LLY

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$309,333,022
+$91,531,486 QoQ
Shares Held
257,900
+8.9% QoQ
Ownership
0.027%
of shares outstanding
% of Portfolio
6.12%
of 13F equity value
Holder Rank
#209
of 4,605 holders
Holding Since
Sep 2022
15 quarters on record
Voting authority Sole 0% Shared 0% None 100%

Common Shares in LLY Over Time

Shares Held

Position Value (USD)

Derivatives in LLY

reported options exposure · as of Sep 30, 2022
CallValue
$4,850,250
CallShares
15,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $634,822,752 across 5 Drug Manufacturers - General names. LLY ranks #1 (48.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
This page
257,900 $309,333,022

All Filings in LLY

Export CSV
15 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $309,333,022 257,900
2026-03-31 $217,801,536 236,800
2025-12-31 $323,693,646 301,200
2025-09-30 $229,815,600 301,200
2025-06-30 $263,169,328 337,600
2025-03-31 $278,827,216 337,600
2024-12-31 $260,627,200 337,600
2024-09-30 $299,093,344 337,600
2024-06-30 $305,656,288 337,600
2024-03-31 $280,687,968 360,800
2023-12-31 $212,998,968 365,400
2023-09-30 $99,906,180 186,000
2023-06-30 $87,230,280 186,000
2023-03-31 $63,876,120 186,000
2022-09-30 $4,850,250 15,000